NVN Liquidation Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Scott Plesha

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	1.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	keine Daten

Jüngste Management Updates

Recent updates

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Jun 07

Novan Q2 2022 Earnings Preview

Aug 10

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Jul 19

Geschäftsführer

Scott Plesha (58 yo)

less than a year

Amtszeit

Mr. Scott M. Plesha is Chief Executive Officer of Ligand Pharmaceuticals Incorporated from April 2024. Mr. Plesha had been the President of BioDelivery Sciences International, Inc. since December 2017 and...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
John Gay	Chief Financial Officer	5.3yrs	US$568.23k	0.17% $ 0.05
Scott Plesha	CEO & Director	less than a year	keine Daten	keine Daten
Carri Geer	Senior VP & CTO	5.3yrs	keine Daten	keine Daten
Sai Rangarao	Senior VP	less than a year	keine Daten	keine Daten
Tomoko Maeda-Chubachi	Chief Medical Officer	2.8yrs	keine Daten	keine Daten
Melvin Whitehead	Senior Vice President of Manufacturing Operations	less than a year	keine Daten	keine Daten

1.6yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: NOVN.QDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.6 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

NVN Liquidation Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Recent updates

Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.

Nasdaq To Delist the Common Stock of Novan

Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite Index

Novan's Securities to Be Delisted from Nasdaq

Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS Requirement

Price target decreased by 12% to US$11.50

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 14% to US$11.50

Consensus EPS estimates fall by 16%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Novan, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 13% to US$12.67

Forecast to breakeven in 2025

Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum Contagiosum

Novan, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novan Q2 2022 Earnings Preview

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Novan Announces Publication of Positive Results from Pivotal Phase 3 Study of Berdazimer Gel, 10.3% (Sb206) in Patients with Molluscum Contagiosum in Jama Dermatology

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $14.968192 million.

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Novan, Inc. to Report Q1, 2022 Results on May 16, 2022

Novan, Inc. to Report Fiscal Year 2021 Results on Feb 22, 2022

Novan Reports Safety Data from B-SIMPLE4 Pivotal Phase 3 Study of SB206

Novan, Inc. has completed a Follow-on Equity Offering in the amount of $40.000004 million.

Novan shares under pressure after proposing capital raise

Novan, Inc. Reports Positive Topline Results from Pivotal Phase 3 Trial of Sb206 in Patients with Molluscum Contagiosum

Novan, Inc. Announces Positive Preclinical Data in SB019 COVID-19 Anti-Viral Therapy Program

Novan, Inc. Announces Results from Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health

Novan, Inc. Announces Final Week-12 Visit for Last Patient in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

Novan, Inc. Appoints Steven D. Skolsky to Its Board

Novan, Inc. Contemplates Bankruptcy

Novan Regains Compliance with Nasdaq Minimum Bid Price Requirement

Novan regains Nasdaq compliance for minimum bid price requirement

Novan Updates Enrollment for Its B-SIMPLE4 Pivotal Phase 3 Study Evaluating SB206

Novan Exceeds 60% Enrollment in B-Simple4 Pivotal Phase 3 Study of Sb206 for Treatment of Molluscum

Novan Receives Approval from the Listing Qualifications Department of the Nasdaq Stock Market

Novan EPS in-line, beats on revenue

Novan, Inc. Announces Positive in vitro Results Showing the Potential Efficacy of Its NITRICIL™ Platform Technology as an Antiviral Against SARS-CoV-2 the Virus That Causes COVID-19

Novan, Inc. Announces the Appointment of John M. Gay as Chief Financial Officer

Novan, Inc. May File for Bankruptcy

Earnings released

Price target lowered to US$2.75

Novan, Inc.(NasdaqGM:NOVN) dropped from Russell Microcap Value Index

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit